Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.21.2
Commitments and Contingencies (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Feb. 03, 2020
USD ($)
milestone
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
therapy
milestone
Aug. 31, 2017
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Aug. 31, 2019
USD ($)
Operating Leased Assets [Line Items]                                  
General and administrative expense         $ 5,188 $ 4,573   $ 16,718 $ 13,350                
Payment received   $ 2,000                              
Period after public launch to terminate agreement   3 years                              
Percentage of net present value of royalty payments   75.00%                              
Aevi                                  
Operating Leased Assets [Line Items]                                  
Milestone payment               0                  
Aevi                                  
Operating Leased Assets [Line Items]                                  
Number of milestones | milestone 2                                
Contingent consideration $ 6,500           $ 6,500                    
Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of milestones | milestone     3                            
Contingent consideration     $ 15,000                            
Milestone payment               0                  
AVTX-801, AVTX-802, And AVTX-803 | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of preclinical therapies | therapy     3                            
AVTX-913 | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of preclinical therapies | therapy     1                            
Milestone One | Aevi                                  
Operating Leased Assets [Line Items]                                  
Contingent consideration 2,000                                
Milestone One | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                     $ 6,000            
Milestone Two | Aevi                                  
Operating Leased Assets [Line Items]                                  
Contingent consideration $ 4,500                                
Milestone Two | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                       $ 5,000          
Milestone Three | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                       $ 4,000          
Alto | AVTX-301 Out-License                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                             $ 18,600    
Revenue recognized from milestones to date         0     0                  
ES | AVTX-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Revenue recognized from milestones to date         0     0                  
ES | AVTX-611 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                                 $ 20,000
Revenue recognized from milestones to date         0     0                  
ES | Milestone One | AVTX-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                           $ 6,000      
ES | Milestone Two | AVTX-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                           $ 20,000      
Janssen Pharmaceuticals, Inc. (Janssen) | AVTX-501                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones       $ 20,000                          
Revenue recognized from milestones to date         0     0                  
Proceeds from sale       $ 25,000                          
Karbinal Agreement | TRIS Pharma                                  
Operating Leased Assets [Line Items]                                  
Minimum quantity required | unit                   70,000              
Make whole payment per unit (in dollars per share) | $ / shares                   $ 30              
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee                               $ 10,000  
Percent of payments received from sublicensing                               30.00%  
Research and development expense               10,000                  
Cumulative expense recognized to date         0     0                  
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                               $ 112,500  
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                               $ 75,000  
AVTX-006 Astellas License Agreement | Astellas Pharma, Inc. (Astellas)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee         500     500                  
Maximum aggregate milestone payment         5,500     5,500                  
Research and development expense               500                  
Cumulative expense recognized to date         500     500                  
AVTX-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee         6,000     6,000                  
Research and development expense               0                  
Cumulative expense recognized to date         1,500     1,500                  
AVTX-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca) | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment         71,500     71,500                  
AVTX-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca) | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment         90,000     90,000                  
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee                         $ 400        
Research and development expense               400                  
Cumulative expense recognized to date         $ 0     0                  
Patent costs                         500        
General and administrative expense               $ 500                  
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                         24,200        
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                         $ 50,000